"Sort of," the PFY nods. "A survey of a couple of inboxes reveals a 'top secret, not to be mentioned to anyone' discussion at ...

Merck agreed to buy Cidara Therapeutics, the maker of an experimental flu therapy, in a $9.2 billion deal, as the ...

Lithium-Ion batteries save weight and help produce improved spark performance. What's not to like? Check out these options.

ESI Motion, a leader in advanced motion and power solutions, proudly announces the release of its next-generation space-rated ...

Energy Plug Technologies and Quantum eMotion have confirmed the launch and first working session of their Joint Development ...

The final panel design was, in fact, two panels. The first was a standard small consumer unit, with four breakers, one ...

Hoover City Schools officially received an overall grade of A on its state report card for the ninth year in a row in an ...

Following the FDA approval of a vagus nerve stimulator for rheumatoid arthritis, supporters of the device’s use have lauded ...

BMS and J&J first linked together in 2018 to develop factor X1a inhibitors as anti-coagulants. The three Phase III Librexia ...

Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.

Bristol Myers Squibb (BMY) stock drops as the company fails in a key Phase 3 trial for milvexian, an anticoagulant it is ...

The Librexia clinical trial program includes two other Phase 3 trials, Librexia AF for patients with atrial fibrillation (AF) and Librexia STROKE for secondary stroke prevention (SSP). The IDMC ...